Challenges and opportunities for human Organ Chips in FDA assessments and pharma pipelines
Cell Stem Cell · 2026-02 · 33 (2) · 176-183
DOI: 10.1016/j.stem.2025.12.022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Stem Cell, 2026-02. Verfasst von Donald E Ingber. Beteiligte Einrichtung: Wyss Institute for Biologically Inspired Engineering at Harvard University, 201 Brookline Ave., Suite 401, Boston, MA 02215, USA; Vascular Biology Pr…. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: DARPA, Pfizer Global Pharmaceuticals, Harvard University Wyss Institute for Biologically Inspired Engineering.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Wyss Institute for Biologically Inspired Engineering at Harvard University, 201 Brookline Ave., Suite 401, Boston, MA 02215, USA; Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvar…
Förderung
- DARPA
- Pfizer Global Pharmaceuticals
- Harvard University Wyss Institute for Biologically Inspired Engineering
- AstraZeneca PLC
- NIH
- ARPA-H
- Cystic Fibrosis Foundation
- Merck Pharmaceuticals
Zitieren
APA
Ingber, D. E. (2026). Challenges and opportunities for human Organ Chips in FDA assessments and pharma pipelines. Cell Stem Cell, 33(2), 176-183. https://doi.org/10.1016/j.stem.2025.12.022
Vancouver
Ingber DE. Challenges and opportunities for human Organ Chips in FDA assessments and pharma pipelines. Cell Stem Cell. 2026;33(2):176-183. doi:10.1016/j.stem.2025.12.022
BibTeX
@article{Ingber2026,
author = {Ingber, Donald E},
title = {Challenges and opportunities for human Organ Chips in FDA assessments and pharma pipelines},
journal = {Cell Stem Cell},
year = {2026},
volume = {33},
number = {2},
pages = {176--183},
doi = {10.1016/j.stem.2025.12.022}
}
EUVIMED